Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash

Gilead subsidiary Kite on Wednesday broadened the scope of its existing collaboration with Arcellx. The two companies will now also evaluate the investigational cell therapy CART-ddBCMA, originally being developed for multiple myeloma, as a treatment for lymphomas.